A more bearish analyst sees the stock at $91 within the next year, while a more bullish analyst sees the stock at $122, within the same time frame. A reading of 1 and 2 represents fairly priced stocks. Its Director Lofton Kevin E sold 3,500 company shares for $286000.9, in a transaction on 2016-08-24. Cypress Wealth Advisors LLC raised its position in Gilead Sciences by 1.4% in the first quarter. Now the stock has been rated as “Buy” from 7 Analysts. Blue Edge Capital LLC raised its stake in Gilead Sciences by 0.7% in the fourth quarter. Value investors believe in the notion that a stock’s current market value essentially doesn’t denote the company’s performance. Carl Domino Inc raised its stake in Gilead Sciences by 0.5% in the second quarter. Stock value has moved between $77.42 – 112.2 in last one year. PacWest Financial Management Inc raised its stake in Gilead Sciences by 0.7% in the first quarter.
Advertisement
Now the return on equity is 100.80% and its debt to equity is 1.42. Finally, Hancock Holding Co. raised its stake in Gilead Sciences by 0.4% in the first quarter. The stock’s low price in its 52 week is $76.94 per share while $113.31 as the 52 week high price. GILD stock trades in the range of $76.94 to $78.46 before the earnings release. The latest trading activity of 12.37 Million shares is above its average volume of 10.18 Million shares.
Gilead Sciences, Inc. has a 50 day moving average of 81.16 and a 200 day moving average of 86.85. The stock has a market capitalization of $101.47 billion and a price-to-earnings ratio of 6.75. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 8.52% since February 1, 2016 and is downtrending. (GILD) is getting weaker by the somewhat negative sentiment (2.2 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Overweight. 11 analysts have suggested the company is a “Hold”. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. During the same period past year, the business posted $3.15 earnings per share.
07/29/2016 – Gilead Sciences, Inc. was downgraded to “hold” by analysts at Argus. “0” issued rating as a “HOLD”. The ex-dividend date is Wednesday, September 14th. It has a dividend yield of 2.40%.
A number of analysts recently commented on the company.
Shares of Gilead Sciences Inc. Leerink Swann reissued an “outperform” rating and issued a $112.00 target price (down previously from $114.00) on shares of Gilead Sciences in a report on Wednesday, August 24th. The company has an Average Rating of 2.34 based on analysts tracked by Thomson Reuters.
Noble Corp. (NYSE:NE)’s stock had its “buy” rating reaffirmed by Credit Suisse Group AG in a note issued to investors on Thursday. Volume of around 9.1 million was about 10% below the daily average of almost 10.2 million. Following the transaction, the Director is left with a stake of 0 shares, now valued at $0. The disclosure for this sale can be found here.
Advertisement
The stats on Gilead Sciences Inc. are now as follows. The Firm focuses on the discovery, development and commercialization of medicines in areas of unmet medical need.
